These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 11567678)

  • 21. Glycoprotein IIb/IIIa receptor antagonists in the treatment of acute ST elevation MI: from hypotheses to unexpected recent observations.
    Ross AM
    J Thromb Thrombolysis; 2003 Apr; 15(2):85-9. PubMed ID: 14618074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary stenting and glycoprotein IIb/IIIa inhibitors in acute myocardial infarction.
    Colombo A; Briguori C
    Am Heart J; 1999 Aug; 138(2 Pt 2):S153-7. PubMed ID: 10426875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glycoprotein IIb/IIIa antagonism and fibrinolytic therapy for acute myocardial infarction.
    Vivekananthan DP; Patel VB; Moliterno DJ
    J Interv Cardiol; 2002 Apr; 15(2):131-9. PubMed ID: 12063808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Glycoprotein IIb/IIIa platelet blockers in acute myocardial infarct treated with primary coronary angioplasty].
    Kala P; Poloczek M; Bocek O; Jerábek P; Neugebauer P; Kosová J; Semrád B
    Vnitr Lek; 2002 Aug; 48(8):736-41. PubMed ID: 12425204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Reperfusion after acute myocardial infarct with fibrinolytic therapy o combination reduced fibrinolytic therapy and a glycoprotein IIb/IIIa inhibitor: the GUSTO V study].
    Franzosi MG
    Ital Heart J Suppl; 2001 Sep; 2(9):1034-6. PubMed ID: 11675828
    [No Abstract]   [Full Text] [Related]  

  • 26. Relationship between therapeutic time intervals and intermediate term left ventricular systolic function in patients treated with facilitated percutaneous coronary intervention for acute myocardial infarction.
    Meyborg P; Abdel-Wahab M; Herrmann G; Geist V; Khattab AA; Krüger D; Lins M; Toelg R; Simon R; Richardt G
    Clin Res Cardiol; 2007 Feb; 96(2):94-102. PubMed ID: 17160565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is transport with platelet GP IIb/IIIa inhibition for primary percutaneous coronary intervention more efficient than on-site thrombolysis in patients with STEMI admitted to community hospitals? Randomised study. Early results.
    Dobrzycki S; Mezyński G; Kralisz P; Prokopczuk P; Nowak K; Kochman W; Zuk J; Bachórzewska-Gajewska H; Sawicki Z; Poniatowski B; Korecki J; Musiał WJ
    Kardiol Pol; 2006 Aug; 64(8):793-9; discussion 800-1. PubMed ID: 16981054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
    Silva MA; Donovan JL; Gandhi PJ; Volturo GA
    Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Intracoronary administration of the combined fibrinolytic therapy a in patient with acute myocardial infarction and end-stage coronary heart disease - a case report].
    Dziewierz A; Dudek D; Bartuś S; Legutko J; Dubiel JS
    Kardiol Pol; 2003 Jan; 58(1):45-8. PubMed ID: 14502303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
    Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P;
    Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines.
    Spinler SA; Hilleman DE; Cheng JW; Howard PA; Mauro VF; Lopez LM; Munger MA; Gardner SF; Nappi JM
    Ann Pharmacother; 2001 May; 35(5):589-617. PubMed ID: 11346067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future.
    De Luca G; Savonitto S; van't Hof AW; Suryapranata H
    Drugs; 2015 Jul; 75(11):1229-53. PubMed ID: 26177890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bridging the gap with new strategies in acute ST elevation myocardial infarction: bolus thrombolysis, glycoprotein IIb/IIIa inhibitors, combination therapy, percutaneous coronary intervention, and "facilitated" PCI.
    Cannon CP
    J Thromb Thrombolysis; 2000 Apr; 9(3):235-41. PubMed ID: 10728022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials).
    Rebeiz AG; Johanson P; Green CL; Crater SW; Roe MT; Langer A; Giugliano RP; Lincoff AM; Newby LK; Harrington RA; Topol EJ; Califf RM; Wagner GS; Krucoff MW
    Am J Cardiol; 2005 Mar; 95(5):611-4. PubMed ID: 15721101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
    Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ;
    Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination therapy for acute myocardial infarction: fibrinolytic therapy and glycoprotein IIb/IIIa inhibition.
    Califf RM
    Am Heart J; 2000 Feb; 139(2 Pt 2):S33-7. PubMed ID: 10650314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in antithrombotic therapy of acute myocardial infarction.
    Gensini GF; Comeglio M; Falai M
    Am Heart J; 1999 Aug; 138(2 Pt 2):S171-6. PubMed ID: 10426878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Platelet GP IIb/IIIa receptor blockers for failed thrombolysis in acute myocardial infarction, alone or as adjunct to other rescue therapies; single centre retrospective analysis of 548 consecutive patients with acute myocardial infarction.
    Ronner E; van Domburg RT; van den Brand MJ; de Feyter PJ; Foley DP; van der Giessen WJ; Serruys PW; Simoons ML
    Eur Heart J; 2002 Oct; 23(19):1529-37. PubMed ID: 12242073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial.
    Lincoff AM; Califf RM; Van de Werf F; Willerson JT; White HD; Armstrong PW; Guetta V; Gibler WB; Hochman JS; Bode C; Vahanian A; Steg PG; Ardissino D; Savonitto S; Bar F; Sadowski Z; Betriu A; Booth JE; Wolski K; Waller M; Topol EJ;
    JAMA; 2002 Nov; 288(17):2130-5. PubMed ID: 12413372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial).
    Cornel JH; Tricoci P; Lokhnygina Y; Moliterno DJ; Wallentin L; Armstrong PW; Aylward PE; Clare RM; Chen E; Leonardi S; Van de Werf F; White HD; Held C; Strony J; Mahaffey KW; Harrington RA
    Am J Cardiol; 2015 May; 115(10):1325-32. PubMed ID: 25776457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.